EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 3

Peppermint oil Mentha x piperita

Also called: peppermint, Menthae piperitae aetheroleum

Peppermint oil is the essential oil extracted from the flowering parts and leaves of peppermint, Mentha x piperita. It is taken by mouth, often in enteric-coated capsules, inhaled or applied to the skin. Peppermint leaf is used for tea.

Category
Botanical
Part used
Essential oil from flowering parts and leaves
Strongest evidence
B Some positive trials
Reviewed
2026-10-28

Class 1 Well studied in people. A 2022 meta-analysis (Aliment Pharmacol Ther) pooled 10 RCTs (1,030 patients) of peppermint oil versus placebo for irritable bowel syndrome. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied3 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Peppermint oil does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Peppermint oil, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Irritable bowel syndrome (IBS) symptomsBA 2022 review of 10 studies (1,030 participants) found enteric-coated peppermint oil better than placebo for overall IBS symptoms, with more, mostly mild, side effects; a 2021 ACG guideline recommended it. [1]
Tension-type headache (applied to skin)CLimited evidence suggests topical peppermint oil may relieve tension headaches. [1]
IndigestionCPeppermint oil combined with caraway oil may relieve indigestion; peppermint oil alone has no such evidence and may worsen indigestion in some people. [1]
Chemotherapy-related nausea and vomitingCNCCIH reports that inhaled peppermint oil or oral peppermint may reduce chemotherapy-related nausea and vomiting. [1]

Main constituents: Menthol [1]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    EU monograph: safety during pregnancy and lactation has not been established …

    2 statements in the profile.

    Details and sources
  • Interactions with medicines
    2 listed

    Antacids, histamine-2 blockers and proton pump inhibitors (gastro-resistant oral forms); CYP3A4 substrates

    Details and sources
  • Cancer evaluations (IARC, NTP)
    2 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    2 statements

    EU (EMA HMPC monograph, Revision 1, 15 January 2020), well-established use, oral: adolescents, adults and elderly 0.2-0.4 ml in solid …

    Details and sources
  • Oral and topical use appear safe at commonly used doses. Oral peppermint oil commonly causes heartburn, nausea, abdominal pain and dry mouth; enteric-coated capsules are designed to reduce heartburn. Allergic reactions are rare. [1]
  • Topical use can cause rashes and irritation. Menthol inhaled by infants or young children can cause serious breathing effects, so the oil should not be applied to their faces. [1]
  • Peppermint in food amounts is likely safe in pregnancy and breastfeeding; little is known about medicinal amounts. Oil used on the nipples should be applied after nursing and wiped off before the next feeding. [1]
Interactions

Interactions

Known interactions of Peppermint oil
WithWhat happens
Medicines in generalNo specific interactions are listed; NCCIH advises talking with a provider before use if you take any medicine. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Regulation

Regulatory status

  • US: sold as a dietary supplement ingredient; dietary supplements are not approved by the FDA before sale, and manufacturers are responsible for safety and labeling. [1]
  • EU: the EMA HMPC lists peppermint oil under well-established use (oral use for minor spasms of the gut, flatulence and abdominal pain, especially in IBS; topical use for mild headache) and traditional use for coughs and colds, muscle pain and itching (revision 1 published 24/07/2020). [2]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Menthol and other terpenic constituents Terpenoids (monoterpenes) [P5]
  • Pulegone and menthofuran (1-11% of the essential oil): constituents with an EU exposure limit Terpenoids (monoterpenes) [P5]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming peppermint oil (earliest NDI 502 submitted 2007-12-03; most recent NDI 503 submitted 2007-12-03). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. Both are multi-ingredient products. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC carcinogenicity evaluation of peppermint oil was found (IARC Monographs list of classifications checked 2026-10-29). IARC classifies pulegone, a constituent, as Group 2B (Volume 108, 2016). [P2]
  • No NTP carcinogenicity technical report on peppermint oil was found (NTP technical reports list checked 2026-10-29). [P3]
  • dl-Menthol (NTP TR-98, 1979, in feed): not carcinogenic for Fischer 344 rats or B6C3F1 mice under the conditions of the bioassay. [P7]
  • EU monograph: tests on reproductive toxicity and carcinogenicity of peppermint oil have not been performed; pulegone and its metabolites caused liver and urinary-tract carcinogenicity in rats and mice, and pulegone and menthofuran are considered non-genotoxic carcinogens acting through sustained cytotoxicity at high doses. [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Antacids, histamine-2 blockers and proton pump inhibitors (gastro-resistant oral forms): Food or antacids taken at the same time could cause early release of the capsule content; H2 blockers and proton pump inhibitors may cause premature dissolution of the enteric coating and should be avoided. [P5]
  • CYP3A4 substrates: In one clinical study with peppermint oil and one with menthol, some inhibition of CYP3A4 activity has been described. [P5]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition-based exemption under 111.75(a)(1)(ii). [P4]
  • Pulegone and menthofuran content — EU monograph: the amount of pulegone and menthofuran has to be specified in the product; daily exposure must be below 37.5 mg per person (below 0.75 mg/kg bw per day for children). [P5]
  • Compliance with the European Pharmacopoeia monograph (ref. 0405) — The EU herbal monograph states the material complies with this Ph. Eur. monograph. [P5]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • Menthol and other terpenic constituents of peppermint oil are fat-soluble and rapidly absorbed in the proximal small intestine; to some extent they are excreted as glucuronides. Peak menthol urinary excretion was lower and delayed with modified-release preparations compared with immediate-release preparations. [P5]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU (EMA HMPC monograph, Revision 1, 15 January 2020), well-established use, oral: adolescents, adults and elderly 0.2-0.4 ml in solid gastro-resistant dosage forms, daily dose 0.6-1.2 ml in two or three doses; children 8-11 years 0.2 ml three times daily; not recommended under 8 years; courses no longer than 3 months. [P5]
  • EU (same monograph), well-established use, cutaneous for mild tension-type headache: adults 10% in ethanol, one application repeatable twice at 15-minute intervals, one treatment daily; not recommended under 18 years. [P5]

Pregnancy and breastfeeding

  • EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use during pregnancy and lactation is not recommended. It is unknown whether peppermint oil constituents are excreted in human breast milk. [P5]
  • NCCIH: oral peppermint in amounts commonly found in food is likely safe during pregnancy or breastfeeding; little is known about medicinal amounts. [P6]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (list last updated 2026-07-23 per page data; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. European Medicines Agency, HMPC. European Union herbal monograph on Mentha x piperita L., aetheroleum, EMA/HMPC/522410/2013, Final - Revision 1 (15 January 2020), 2020-01-15. ema.europa.eu
  6. NCCIH. Peppermint Oil (Last Updated: May 2025), 2025-05. nccih.nih.gov
  7. National Toxicology Program. TR-98: Bioassay of dl-Menthol for Possible Carcinogenicity (CASRN 89-78-1) (1979), 1979. ntp.niehs.nih.gov
Sources

Sources

  1. NCCIH. Peppermint Oil (Last Updated: May 2025), 2025-05. nccih.nih.gov
  2. European Medicines Agency. Menthae piperitae aetheroleum (herbal medicine page), 2020-07-24. ema.europa.eu
  3. Ingrosso MR, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 2022;56(6):932-941 (PMID 35942669), 2022-08-09. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.